Bellerophon Therapeutics Inc

NASDAQ:BLPH  
0.97
+0.05 (+4.95%)
Products

Bellerophon Announces FDA Acceptance Of Change To Ongoing Phase 3 Rebuild Study Of Inopulse

Published: 09/27/2022 13:29 GMT
Bellerophon Therapeutics Inc (BLPH) - Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 Rebuild Study of Inopulse® for Treatment of Fibrotic Interstitial Lung Disease.
Bellerophon Therapeutics Inc - Enrollment Now Expected to Conclude in Q1 2023, With Pivotal Top-line Data Readout Anticipated in Q3 2023.
Bellerophon Therapeutics Inc - Enrollment Now Expected to Conclude in Q1 2023, With Pivotal Top-line Data Readout Anticipated in Q3 2023.